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Abstract: COPD is a major cause of chronic morbidity and mortality worldwide, and there 
is a need to develop more effective therapeutic strategies to replace specialized treatment such 
as lung transplantation. Recent studies suggest that recognition of apoptotic lung epithelial or 
endothelial cells may result in growth factors to stimulate cell replacement, and defects in these 
processes may contribute to the pathogenesis of COPD. Furthermore, recent animal and human 
studies have revealed that tissue-speciﬁ  c stem cells and bone marrow-derived cells contribute to 
lung tissue regeneration and protection, and thus administration of exogenous stem/progenitor 
cells or humoral factors responsible for activation of endogenous stem/progenitor cells may be 
a potent next-generation therapy for COPD.
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Introduction
COPD is a major cause of chronic morbidity and mortality worldwide, and the World 
Health Report 2004 from WHO estimated 2.75 million deaths by COPD in 2002 (WHO 
2004). Pulmonary emphysema, a major component of the morbidity and mortality in 
COPD, is characterized by permanent enlargement of airspaces distal to the terminal 
bronchiole, accompanied by destruction of their walls (Wright and Churg 2006). Only 
cigarette smoking cessation and long-term oxygen therapy improve survival in COPD 
(Celli and MacNee 2004; Anthonisen et al 2005), and patients with severe COPD 
require invasive treatment such as lung transplantation. Therefore, there is a need to 
develop less invasive, more effective therapeutic strategies for COPD.
It has been demonstrated that all-trans-retinoic acid (ATRA), a metabolite of 
retinol associated with the process of alveolar septation (Ong and Chytil 1976), can 
restore the normal lung structure in rats with emphysema (Massaro and Massaro 
1997), suggesting the possibility of tissue regeneration in COPD. Since then, a number 
of studies demonstrating lung repair by means of stem/progenitor cells or humoral 
factors have been reported in animal models. This article reviews recent advances in 
regenerative medicine in COPD and its potential application.
Lung repair mechanisms in COPD
Apoptotic clearance in COPD
It has been reported that cell death in epithelial and endothelial alveolar cells are 
increased in patients with pulmonary emphysema (Kasahara et al 2001; Yokohori 
et al 2004). In general, apoptotic cells are removed from tissues, followed by cell 
replacement to maintain homeostasis. Recognition of apoptotic cells initiates 
production of growth/maintenance factors for both epithelial and endothelial cells, and 
stimulates endothelial angiogenic responses (Weihua et al 2005). Thus, signals from 
apoptotic cell recognition may contribute to stimulation, release, and/or attraction of 
progenitor cells for tissue regeneration (Henson et al 2006). Therefore, the presence International Journal of COPD 2008:3(4) 510
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of apoptotic cells in COPD may imply defects in these 
clearance mechanisms (Henson et al 2006). In fact, there is 
increasing evidence that apoptotic clearance mechanisms 
are less effective in COPD lungs and that macrophages from 
such lungs show a defect in recognizing and ingesting such 
targets (Hodge et al 2003).
Tissue-speciﬁ  c stem cells in the lung
In the lung, epithelial stem cells include type II pneumocyte 
in the alveolus and the Clara cell in the bronchiole (Mason 
et al 1997; Majka et al 2005). Reddy et al demonstrated that 
E-cadherin-negative subpopulation of type II cells were 
proliferative and exhibited high levels of telomerase activity 
(Reddy et al 2004). Kim et al isolated a pulmonary stem cell 
population at the bronchioalveolar duct junction, and it may 
maintain alveolar type II cells of the distal lung and Clara 
cells in the bronchiole (Kim et al 2005). Hong et al also 
demonstrated that tracheal basal cells represent a multipotent 
progenitor cell type for renewal of the injured tracheal 
epithelium induced by naphthalene (Hong et al 2004). On 
the other hand, side population (SP) cells, which are more 
primitive adult stem cells and found in various tissues, have 
been recently identiﬁ  ed in the lung tissue (Summer et al 
2003; Summer et al 2004). SP cells comprise 0.03%–0.07% 
of mouse lung cells and are sca-1-positive, lineage-negative, 
and heterogenous at CD45. In addition, Giangreco et al 
indicated that sca-1-positive, CD45-negative SP cells from 
mouse lung had a molecular phenotype similar to neuroepi-
thelial body-associated variant Clara cells (Giangreco et al 
2004), which are label-retaining cells with multipotency 
(Hong et al 2001).
Bone marrow-derived
stem/progenitor cells
It has been demonstrated that circulating endothelial 
progenitor cells (EPC) are decreased in COPD patients and 
could be correlated with disease severity (Fadini et al 2006; 
Palange et al 2006). These results raise the possibility that 
bone marrow cells may be involved in lung regeneration or 
protection. EPC have been mobilized into the circulation 
in mice with lipopolysaccharide (LPS)-induced lung 
injury (Yamada et al 2004) and in patients with bacterial 
pneumonia (Yamada et al 2005), and large numbers of bone 
marrow-derived progenitor cells appeared in active ﬁ  brotic 
lesions in the lung of bleomycin-treated mice (Hashimoto 
et al 2004). However, whether EPC plays a role in the 
loss of capillaries, in the remodeling of the vascular bed 
or in the thickening of the small airway wall remains to 
be elucidated (Randell 2006). In human lung allografts, 
recipient-derived cells were integrated into pulmonary 
epithelium, and epithelial chimerism occurred in bronchi, 
type II pneumocytes and seromucous glands surrounding 
larger bronchi (Kleeberger et al 2003). Suratt et al examined 
human lung specimens from a retrospective cohort of female 
allogeneic hematopoietic stem cell transplantat recipients 
who received stem cells from male donors, and found signiﬁ  -
cant rates of epithelial (3%–8%) and endothelial (38%–42%) 
chimerism (Suratt et al 2003).
Potential strategies for tissue 
regeneration in COPD
Administration of humoral factors 
responsible for lung regeneration
Because recognition of apoptotic cells by macrophages in 
COPD is related to the production of hepatocyte growth 
factor (HGF) by these macrophages, administration of HGF 
might compensate for the defects in apoptotic clearance 
in COPD macrophages (Morimoto et al 2001). It has been 
demonstrated that HGF induces angiogenesis in elastase-
injured lung injury through mobilizing endothelial progenitor 
cells (Ishizawa et al 2004b). In addition, induction of 
HGF expression by a gene-transfection method resulted 
in improved pulmonary function via inhibition of alveolar 
cell apoptosis, enhancement of alveolar regeneration, and 
promotion of angiogenesis in rats with elastase-induced 
emphysema (Shigemura et al 2005).
Fibroblast growth factor-2 (FGF-2), an angiogenic 
factor indispensable for lung development and branching 
morphogenesis, has been shown to induce an increase in 
pulmonary blood ﬂ  ow in the damaged lung and a volume 
reduction in the emphysematous lung, and lead to recovery 
of pulmonary function in dogs with emphysema (Morino 
et al 2005); however, FGF-2 could not achieve parechymal 
regeneration and alveolar septation.
Vascular endothelial growth factor (VEGF) is a potent 
mediator of angiogenesis and vascular permeability (Ribatti 
2005), and may be involved in many processes in COPD 
including pulmonary vascular remodeling and endothelial 
and epithelial cell apoptosis (Papaioannou et al 2006). The 
complexity of the roles of VEGF and its receptors suggests 
that strategies speciﬁ  cally targeting VEGF in COPD would 
have unpredictable and possibly deleterious effects on some 
of the different processes (Kanazawa 2007).
ATRA (Massaro and Massaro 1997; Belloni et al 2000) 
or granulocyte-colony-stimulating factor (G-CSF) promoted International Journal of COPD 2008:3(4) 511
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lung regeneration and increased bone marrow-derived cell 
numbers in alveoli in mice with elastase-induced emphysema 
(Ishizawa et al 2004a). However, the effect of ATRA in the 
treatment of pulmonary emphysema in animals and humans 
remains controversial (Massaro and Massaro 2000; Mao et al 
2002; Fujita et al 2004; March et al 2004; Roth et al 2006). 
The Feasibility of Retinoids for the Treatment of Emphysema 
(FORTE) study was established by the National Institutes 
of Health/National Heart, Lung, and Blood Institute as an 
initial step in evaluating the clinical feasibility of retinoid-
based therapy (Roth et al 2006). No deﬁ  nitive clinical beneﬁ  t 
related to the administration of retinoids was observed. 
However, time- and dose-dependent changes in DLCO, CT 
density mask score, and health-related QOL were observed 
in subjects treated with ATRA, suggesting the possibility 
of exposure-related biological activity that warrants further 
investigation.
We have demonstrated that adrenomedullin (AM), 
a potent vasodilator peptide, improves elastase-induced 
emphysema (Murakami et al 2005). In this study, AM 
infusion signiﬁ  cantly inhibited the increase in lung volume, 
static lung compliance, and mean linear intercept in mice 
given elastase. AM increased the numbers of mononuclear 
cells and sca-1-positive cells in circulating blood, and 
signiﬁ  cantly increased the number of bone marrow-derived 
cells incorporated into the elastase-treated lung. In vitro, 
addition of AM attenuated elastase-induced cell death in 
alveolar epithelial cells and endothelial cells. These results 
suggest that AM improves emphysema at least in part through 
mobilization of bone marrow cells and direct protective 
effects on alveolar epithelial cells and endothelial cells. AM 
also ameliorated LPS-induced acute injury in rats (Itoh et al 
2007), possibly through inhibition of inﬂ  ammation, hyper-
permeability, and alveolar wall cell apoptosis.
Administration of exogenous stem/
progenitor cells
After intravenous administration of lacZ-labeled bone 
marrow-derived cells into wild-type recipient mice with 
bleomycin-induced lung injury, cells were engrafted 
in recipient lung parenchyma with the phenotype of 
type I pneumocytes of the alveolar epithelium (Kotton et al 
2001). On the other hand, male whole bone marrow cells or 
CD34+lin− bone marrow cells differentiated into bronchiolar 
epithelia and type II alveolar cells after transplantation into 
lethally irradiated female mice (Krause et al 2001; Theise 
et al 2002). Because differentiation into inflammatory 
cells was not observed, these ﬁ  ndings suggest the potential 
application of bone marrow-derived cells for therapy of lung 
diseases including COPD. However, several groups did not 
ﬁ  nd evidence of pulmonary repopulation via bone marrow-
derived cells (Davies et al 2002; Wagers et al 2002; Kotton 
et al 2005; Zander et al 2006), raising the possibility of a 
dominant role of resident lung stem cells in alveolar repair 
and regeneration.
Mesenchymal stem cells (MSC) reside in bone marrow 
(Friedenstein et al 1976), adipose tissue (Gimble and Guilak 
2003), and many other tissues (Pittenger and Martin 2004). 
A recent study suggested that MSC reside in virtually all post-
natal organs and tissues, and may be localized to vessel walls 
(da Silva Meirelles et al 2006). MSC can differentiate not only 
into osteoblasts, chondrocytes, and adipocytes, but also other 
types of cells such as vascular endothelial cells (Pittenger et al 
1999). It has been demonstrated that transplanted MSC home 
to the lung in response to bleomycin-induced lung injury and 
adopt phenotypes of alveolar epithelial cells, endothelial 
cells, ﬁ  broblasts and bronchial epithelial cells, and protect 
lung tissue through suppression of proinﬂ  ammatory cytokines 
such as TNF-α and IL-1, and through triggering production 
of reparative growth factors (Ortiz et al 2003; Rojas et al 
2005; Ortiz et al 2007). Shigemura et al demonstrated that 
autologous transplantation of adipose tissue-derived MSC 
ameliorates pulmonary emphysema in rats (Shigemura et al 
2006b), and accelerates alveolar and vascular regeneration 
after lung volume reduction surgery in rats with emphysema 
(Shigemura et al 2006a).
However, whether exogenous administration of those 
cells improves COPD in humans remains to be elucidated. 
In addition, recent studies demonstrated that cellular senes-
cence is observed in epithelium and endothelium as well as 
in ﬁ  broblasts (Muller et al 2006; Tsuji et al 2006), raising 
the possibility that stem/progenitor cells are also associated 
with senescence (Sharpless and DePinho 2007). Accord-
ingly, it is not clear which type of cells (including adult 
cells or embryonic cells) could be adopted for the treatment 
of COPD, and if it will be possible to repair emphysema or 
to prevent it.
Importance of cigarette smoke cessation 
and exercise
Cigarette smoke causes apoptosis and an inﬂ  ammatory 
response in the lower respiratory tract, impairs the repair 
functions of ﬁ  broblasts, epithelial cells and mesenchymal 
cells, and induces senescence of lung ﬁ  broblasts (Spurzem 
and Rennard 2005; Nyunoya et al 2006; Rennard et al 
2006). Although a reduction in inﬂ  ammation is observed International Journal of COPD 2008:3(4) 512
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after smoking cessation in COPD patients, histopathological 
studies show persistent airway inﬂ  ammation (Willemse et al 
2004). Since cigarette smoke cessation improves respira-
tory symptoms and slows the rapid FEV1 decline in COPD 
patients, it is apparent that cigarette smoke cessation is the 
primary therapeutic intervention for these patients, not only 
as therapeutic basis but also as ethical and economical view-
points. However, the exact mechanism of the reduction in 
airway inﬂ  ammation and the relationship with lung function 
and regeneration after cigarette smoke cessation remain to 
be established.
Exercise might be another approach, because mobilization 
of endothelial progenitor cells occurs after exercise (Rehman 
et al 2004). In addition, several studies have provided 
evidence that exercise improves several of the variables 
associated with poor outcomes such as exercise capacity and 
dyspnea as well as the multidimensional BODE index (Celli 
et al 2004; Cote and Celli 2005; Nici et al 2006). Therefore, it 
is interesting to speculate that the gain in exercise tolerance is 
achieved through mobilization of endothelial progenitor cells. 
Palange et al reported that circulating progenitor count was 
unchanged after endurance exercise in patients with COPD; 
however, this might have been due to insufﬁ  cient intensity 
and/or duration of the test (Palange et al 2006).
Conclusions
Growing evidence obtained from basic and translational 
research on regenerative medicine in COPD suggests that, in 
addition to cigarette smoking cessation and exercise, adminis-
tration of humoral factors responsible for activation of endog-
enous stem/progenitor cells or administration of exogenous 
stem/progenitor cells may be a potential therapeutic tool 
in the treatment of COPD (Table 1). However, in addition 
to clarifying beneficial effects and their mechanism of 
tissue repair and regeneration by administration of humoral 
factors or exogenous stem/progenitor cells, harmful aspects 
including tumor formation should be carefully assessed. 
Therefore, we are at a very initial stage, and tissue regen-
eration for COPD patients, although very attractive, is still 
a far away option.
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